{
    "nctId": "NCT05950945",
    "briefTitle": "Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer",
    "officialTitle": "A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15)",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 250,
    "primaryOutcomeMeasure": "Time From the Start of T-DXd to Initiation of Subsequent Anticancer Treatment (TTNT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Sign and date the main informed consent form\n* Must agree to provide a newly obtained or archival baseline biopsy from primary and/or metastatic lesion.\n* Pathologically documented Breast Cancer (BC) tumor\n\n  * Is unresectable and/or metastatic.\n  * Is hormone receptor-negative or hormone receptor-positive.\n\n    * Must include percentage of positively stained cells to characterize if hormone receptor-positive or -negative.\n  * Has confirmed HER2 IHC 1+ or IHC 2+/ISH- (HER2-low) status or HER2 IHC 0 status as determined according to ASCO CAP 2018 guidelines1 based on sample collected during Tissue Screening as described above.\n  * Was never previously HER2-positive (IHC 3+ or IHC 2+/ISH+) on prior pathology testing (per ASCO CAP guidelines).\n  * Was never previously treated with anti-HER2 therapy in the metastatic setting.\n* Has had at least one and up to two prior lines of therapy in the metastatic setting.\n\n  * In participants with hormone receptor-positive HER2-low metastatic BC (Cohort 3):\n\n    * Has recurrent disease \\<2 years from the initiation of adjuvant ET OR\n    * Has disease progression on CDK4/6 inhibitor-based regimen within 12 months of completion of adjuvant therapy with a CDK4/6 inhibitor OR\n    * Has disease progression within the first 12 months of CDK4/6 in the first line metastatic setting\n* Presence of at least one measurable lesion based on computed tomography or magnetic resonance imaging.\n* Participants with brain metastases are allowed in the study. The brain lesion(s) should be small (\\<2 cm), untreated, asymptomatic, not requiring urgent medical intervention, and are asymptomatic and clinically stable.\n* Has an Eastern Cooperative Oncology Group performance status of 0 or 1.\n* Has a minimum life expectancy of 12 weeks at Screening.\n* Has a left ventricular ejection fraction \u226550% within 28 days before enrollment.\n* Has adequate organ and bone marrow function within 28 days before enrollment.\n* Has adequate treatment washout period before enrollment.\n* Male and female subjects of reproductive/childbearing potential must agree to use a highly effective form of contraception.\n\nExclusion Criteria:\n\n* Prior treatment with an antibody drug conjugate (ADC).\n* Uncontrolled or significant cardiovascular disease.\n* Has a corrected QT interval prolongation.\n* Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.\n* Has spinal cord compression or clinically active central nervous system metastases.\n* Has multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, other solid tumors curatively treated, or contralateral BC.\n* Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug product.\n* Has a history of severe hypersensitivity reactions to other monoclonal antibodies.\n* Has an uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals.\n* Active primary immunodeficiency, known uncontrolled active human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection.\n* Has history of receiving a live, attenuated vaccine (messenger RNA and replication-deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first exposure to study drug.\n* Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade \u22641 or baseline.\n* Is pregnant or breastfeeding or planning to become pregnant.\n* Lung-specific intercurrent clinically significant illnesses.\n* Any autoimmune, connective tissue, or inflammatory disorders.\n* Prior complete pneumonectomy.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}